The expanded interchangeability now applies to the 40mg prefilled syringe and the 40mg and 80mg autoinjectors, in addition to the 20mg and 80mg prefilled syringes. The Food and Drug Administration ...

Credit: Celltrion. Yuflyma, a tumor necrosis factor blocker, was approved in May 2023 as a biosimilar to Humira. Similar PK, efficacy, safety, and immunogenicity data were observed between the ...

Please provide your email address to receive an email when new articles are posted on . Hadlima was approved as a biosimilar to Humira in 2019. The drug is available in a pre-filled syringe or a ...

Please provide your email address to receive an email when new articles are posted on . Quallent will offer both low- and high-concentration citrate-free adalimumab-adbm. The existing biosimilar ...

The Food and Drug Administration has designated Celltrion’s Yuflyma (adalimumab-aaty), as an interchangeable biosimilar to Abbvie's Humira (adalimumab). Yuflyma is a high-concentration (100mg/ml) and ...

Tennessee last year spent $48 million on a single drug, Humira — about $62,000 for each of the 775 patients who were covered by its employee health insurance program and receiving the treatment. So ...

A long-awaited moment for consumers arrived last year when patent protection expired on the nation’s most prescribed medicine, AbbVie’s wildly successful — and costly — rheumatoid arthritis drug ...

In the last month, the FDA has granted interchangeability status to additional adalimumab biosimilars. Biosimilars with an interchangeable designation may be substituted for the reference product at ...

GoodRx (NASDAQ:GDRX) and Boehringer Ingelheim on Thursday announced an initiative to launch the German drugmaker’s biosimilar against AbbVie’s (NYSE:ABBV) Humira (adalimumab) at an exclusively low ...